▁Introduction 7.82421875
: 1.9072265625
<0x0A> 6.53125
In 3.4140625
▁a 3.435546875
▁significant 6.97265625
▁development 2.3359375
▁within 6.96484375
▁the 0.301025390625
▁field 2.75
▁of 0.03997802734375
▁on 8.0703125
colog 3.15625
ical 0.364013671875
▁research 2.482421875
, 0.1959228515625
▁Ch 7.5703125
iros 7.9296875
cience 0.1485595703125
▁Group 5.19921875
▁pl 4.12109375
c 0.0018053054809570312
▁has 1.685546875
▁announced 1.84765625
▁the 1.07421875
▁init 4.34375
iation 0.00041174888610839844
▁of 0.01092529296875
▁human 4.8671875
▁tri 1.021484375
als 0.00034546852111816406
▁for 1.123046875
▁two 4.83203125
▁prom 4.875
ising 0.002689361572265625
▁anti 2.966796875
- 0.0192718505859375
can 0.0908203125
cer 0.0005173683166503906
▁comp 1.9755859375
ounds 0.0035800933837890625
. 1.0029296875
▁This 3.134765625
▁p 6.87109375
iv 1.03515625
otal 0.0007205009460449219
▁step 2.240234375
▁forward 2.650390625
▁show 6.90625
cases 0.00736236572265625
▁the 0.283935546875
▁company 1.5849609375
' 1.4169921875
s 0.000553131103515625
▁commit 0.859375
ment 0.00023853778839111328
▁to 0.036041259765625
▁finding 3.994140625
▁innov 1.09375
ative 0.0008449554443359375
▁solutions 0.55908203125
▁in 3.61328125
▁the 0.178466796875
▁battle 2.169921875
▁against 0.0090789794921875
▁cancer 0.07159423828125
, 1.4619140625
▁bol 8.2109375
ster 0.004489898681640625
ing 0.25634765625
▁hopes 4.890625
▁for 0.3564453125
▁en 6.64453125
hanced 0.07952880859375
▁treatment 1.1318359375
▁options 0.37841796875
, 6.046875
▁improved 1.3759765625
▁patient 0.4326171875
▁out 0.059906005859375
comes 0.00017690658569335938
, 0.228759765625
▁and 0.00555419921875
▁a 1.5732421875
▁br 0.814453125
ighter 2.1457672119140625e-05
▁future 0.0247802734375
▁in 2.3828125
▁the 0.89599609375
▁fight 0.340087890625
▁against 0.00849151611328125
▁this 0.5380859375
▁dev 0.270263671875
ast 5.6862831115722656e-05
ating 0.0005736351013183594
▁disease 0.03582763671875
. 0.01617431640625
<0x0A> 0.1732177734375
Body 11.328125
: 0.2271728515625
<0x0A> 6.80859375
Ch 1.1962890625
iros 0.031463623046875
cience 0.000431060791015625
▁Group 0.0892333984375
▁pl 0.08447265625
c 4.673004150390625e-05
, 1.0966796875
▁a 0.1519775390625
▁ren 3.814453125
owned 0.0003383159637451172
▁global 2.91015625
▁bi 2.326171875
oph 1.19140625
arma 0.0012273788452148438
ce 0.02874755859375
ut 9.906291961669922e-05
ical 0.0001138448715209961
▁company 0.128662109375
▁with 3.607421875
▁a 0.257568359375
▁strong 1.7578125
▁discipl 13.7890625
inary 1.25
▁focus 0.9296875
▁on 0.353515625
▁scientific 5.9765625
▁research 0.9208984375
▁and 0.59765625
▁development 0.8818359375
, 0.2237548828125
▁has 0.310546875
▁been 4.17578125
▁at 0.9150390625
▁the 0.0005030632019042969
▁fore 0.00865936279296875
front 9.965896606445312e-05
▁of 0.006488800048828125
▁cancer 2.6328125
- 3.109375
related 0.5595703125
▁innov 3.01171875
ations 1.130859375
. 1.5693359375
▁With 2.126953125
▁a 1.037109375
▁strong 3.71484375
▁emphas 2.037109375
is 0.00022363662719726562
▁on 0.004894256591796875
▁understanding 4.62109375
▁the 0.2939453125
▁bi 2.60546875
ological 0.63134765625
▁mechan 0.88623046875
isms 0.000804901123046875
▁that 2.0703125
▁under 0.76611328125
lie 0.771484375
▁various 3.58984375
▁forms 1.521484375
▁of 0.005405426025390625
▁cancer 0.14208984375
, 0.213623046875
▁Ch 1.8818359375
iros 0.00200653076171875
cience 0.0004622936248779297
▁has 1.1787109375
▁emb 5.2890625
ark 0.06475830078125
ed 7.748603820800781e-06
▁on 0.0293121337890625
▁an 1.8818359375
▁ar 6.06640625
du 0.01453399658203125
ous 7.164478302001953e-05
▁journey 0.24169921875
▁to 0.53564453125
▁identify 2.728515625
▁effective 3.12890625
▁comp 3.369140625
ounds 0.0022220611572265625
▁that 0.4775390625
▁could 2.349609375
▁revolution 3.40625
ize 0.060455322265625
▁cancer 1.55859375
▁treatment 0.237548828125
▁parad 7.8671875
ig 0.00011670589447021484
ms 0.003658294677734375
. 0.05810546875
<0x0A> 0.44482421875
Under 6.0859375
▁the 0.8125
▁guidance 1.728515625
▁of 0.04681396484375
▁a 2.583984375
▁dedicated 2.208984375
▁team 0.43603515625
▁of 0.0202789306640625
▁mult 6.23828125
id 0.0303497314453125
is 0.0022258758544921875
cipl 3.3974647521972656e-05
inary 0.0004177093505859375
▁research 1.7841796875
ers 0.0609130859375
, 0.38916015625
▁Ch 0.497314453125
iros 0.000820159912109375
cience 0.00020754337310791016
▁has 0.2242431640625
▁successfully 3.0546875
▁gar 8.578125
ner 2.7418136596679688e-06
ed 6.246566772460938e-05
▁attention 3.498046875
▁through 2.439453125
▁its 0.68408203125
▁recent 2.951171875
▁announ 1.0498046875
cement 0.016632080078125
▁of 0.250244140625
▁the 0.728515625
▁init 0.1610107421875
iation 4.57763671875e-05
▁of 0.0004982948303222656
▁human 0.09173583984375
▁tri 0.036224365234375
als 7.867813110351562e-06
▁for 0.027069091796875
▁two 0.04742431640625
▁anti 3.345703125
- 0.00030422210693359375
can 0.0020198822021484375
cer 3.528594970703125e-05
▁comp 0.0294189453125
ounds 0.0009417533874511719
. 0.474609375
▁These 0.90576171875
▁comp 0.59228515625
ounds 0.0003292560577392578
, 0.37109375
▁met 8.8984375
icul 3.2109375
ously 0.0004458427429199219
▁selected 1.6875
▁based 2.1953125
▁on 0.0008087158203125
▁prom 5.71484375
ising 0.0004477500915527344
▁pre 0.60302734375
- 1.2578125
cl 0.003231048583984375
in 1.3470649719238281e-05
ical 0.00017654895782470703
▁results 1.384765625
, 0.142578125
▁hold 3.404296875
▁the 1.8388671875
▁potential 0.10107421875
▁to 0.040496826171875
▁significantly 1.5068359375
▁impact 1.4873046875
▁the 0.4921875
▁lives 3.173828125
▁of 0.0017194747924804688
▁cancer 0.810546875
▁patients 0.01361083984375
▁glob 3.42578125
ally 7.152557373046875e-07
. 0.123046875
<0x0A> 0.1483154296875
Wh 4.0234375
ile 0.0028209686279296875
▁Ch 2.888671875
iros 0.0017795562744140625
cience 0.0001304149627685547
▁has 1.501953125
▁been 1.5087890625
▁relatively 6.2265625
▁tight 2.16015625
- 0.00315093994140625
li 0.00028228759765625
pped 1.811981201171875e-05
▁about 0.35302734375
▁the 0.07220458984375
▁specific 0.6689453125
s 0.42626953125
▁of 0.051788330078125
▁the 0.7451171875
▁comp 0.919921875
ounds 0.005962371826171875
▁under 1.7138671875
▁investigation 1.140625
, 0.023162841796875
▁it 1.203125
▁is 0.54248046875
▁evident 2.220703125
▁that 0.045867919921875
▁the 0.7548828125
▁company 0.20654296875
' 1.7568359375
s 8.666515350341797e-05
▁scientific 4.28125
▁pro 2.50390625
w 0.0012540817260742188
ess 2.300739288330078e-05
▁and 0.78076171875
▁dil 5.203125
igent 0.412841796875
▁research 1.2138671875
▁have 1.5927734375
▁led 1.9921875
▁to 0.06787109375
▁the 0.61865234375
▁identification 1.1708984375
▁of 0.0173187255859375
▁prom 2.740234375
ising 0.00014925003051757812
▁candidates 0.91162109375
. 1.083984375
▁These 2.39453125
▁comp 0.64306640625
ounds 9.691715240478516e-05
, 1.24609375
▁designed 4.0546875
▁to 0.1805419921875
▁target 0.5654296875
▁specific 0.79150390625
▁mole 1.87890625
cular 0.0679931640625
▁path 0.354248046875
ways 0.0005288124084472656
▁within 3.341796875
▁cancer 0.6484375
▁cells 0.01134490966796875
, 0.0267181396484375
▁hold 2.33984375
▁the 0.58642578125
▁promise 2.568359375
▁of 0.040435791015625
▁over 4.80859375
coming 0.054443359375
▁critical 6.21484375
▁obst 2.361328125
acles 0.00019371509552001953
▁faced 2.833984375
▁by 0.1947021484375
▁conventional 1.81640625
▁cancer 0.54638671875
▁treat 0.71728515625
ments 8.344650268554688e-06
. 0.6416015625
<0x0A> 0.095458984375
Ch 2.158203125
iros 0.0142059326171875
cience 9.715557098388672e-05
' 0.267333984375
s 0.00025391578674316406
▁CE 6.98046875
O 0.0005173683166503906
, 0.11920166015625
▁Dr 0.7890625
. 0.03753662109375
▁Em 6.5703125
ily 2.51171875
▁Carter 6.23046875
, 0.053924560546875
▁expressed 2.357421875
▁her 0.451416015625
▁enthus 1.44140625
ias 0.00244903564453125
m 8.940696716308594e-06
▁for 0.869140625
▁the 0.1397705078125
▁human 2.564453125
▁trial 2.125
▁phase 2.54296875
, 0.50634765625
▁stating 0.6474609375
, 2.056640625
▁" 0.03521728515625
Th 3.451171875
ese 0.0004467964172363281
▁anti 5.125
- 0.00012791156768798828
can 0.002315521240234375
cer 0.00022971630096435547
▁comp 0.037628173828125
ounds 0.0005717277526855469
▁represent 1.140625
▁the 2.5859375
▁cul 0.43408203125
min 1.0728836059570312e-06
ation 8.094310760498047e-05
▁of 0.00010979175567626953
▁years 0.5400390625
▁of 0.002521514892578125
▁t 2.61328125
ire 0.047821044921875
less 0.0001100301742553711
▁efforts 2.607421875
▁in 3.734375
▁our 1.6171875
▁labor 1.984375
ator 0.06591796875
ies 1.811981201171875e-05
. 0.90087890625
▁We 0.408447265625
▁firm 4.79296875
ly 9.5367431640625e-07
▁believe 0.00171661376953125
▁that 0.0643310546875
▁they 1.5986328125
▁possess 4.0546875
▁the 0.27783203125
▁potential 0.1510009765625
▁to 0.0059356689453125
▁make 3.06640625
▁a 0.0703125
▁substantial 3.826171875
▁difference 0.9345703125
▁in 0.037384033203125
▁the 0.10662841796875
▁lives 0.293701171875
▁of 0.0003948211669921875
▁cancer 0.3505859375
▁patients 0.00508880615234375
, 1.013671875
▁sh 8.796875
ifting 0.4990234375
▁the 0.08740234375
▁parad 0.85400390625
ig 1.8358230590820312e-05
m 0.059661865234375
▁of 0.2568359375
▁treatment 1.8505859375
▁towards 1.7666015625
▁more 0.66015625
▁target 1.7265625
ed 0.002506256103515625
, 1.53515625
▁effective 1.0078125
, 0.1640625
▁and 0.00203704833984375
▁personal 3.4765625
ized 0.0030059814453125
▁ther 2.857421875
ap 0.043731689453125
ies 1.2040138244628906e-05
." 0.3125
<0x0A> 0.019561767578125
The 1.0888671875
▁comm 2.91015625
enc 0.0016489028930664062
ement 2.0503997802734375e-05
▁of 0.00011169910430908203
▁human 0.11151123046875
▁tri 0.01535797119140625
als 2.1457672119140625e-06
▁is 1.353515625
▁a 0.231201171875
▁critical 3.0
▁mil 0.464111328125
estone 4.1961669921875e-05
▁for 1.2890625
▁Ch 0.1334228515625
iros 0.0002332925796508789
cience 6.103515625e-05
▁Group 2.3046875
▁pl 0.09027099609375
c 7.033348083496094e-06
, 0.19384765625
▁mark 2.12890625
ing 2.1457672119140625e-06
▁the 0.83056640625
▁transition 1.759765625
▁from 0.208740234375
▁pre 1.193359375
- 0.0716552734375
cl 0.0004448890686035156
in 1.430511474609375e-06
ical 3.337860107421875e-05
▁success 8.8828125
▁to 0.175048828125
▁real 2.46484375
- 0.00449371337890625
world 0.057281494140625
▁application 1.1923828125
. 0.10955810546875
▁The 1.310546875
▁human 4.26171875
▁trial 0.84228515625
▁phase 0.11572265625
▁will 1.4150390625
▁offer 4.52734375
▁in 1.859375
valu 0.01305389404296875
able 1.3947486877441406e-05
▁ins 0.11968994140625
ights 1.9073486328125e-06
▁into 0.054412841796875
▁the 0.010650634765625
▁comp 2.693359375
ounds 0.0277557373046875
' 0.006114959716796875
▁effic 1.1513671875
acy 7.033348083496094e-06
, 0.62109375
▁to 2.50390625
x 0.07562255859375
icity 1.2516975402832031e-05
, 0.103271484375
▁and 0.03271484375
▁potential 1.1396484375
▁side 1.783203125
▁effects 0.0197601318359375
▁when 7.3671875
▁admin 0.66748046875
ister 2.3603439331054688e-05
ed 0.0002396106719970703
▁to 0.1187744140625
▁actual 3.396484375
▁cancer 1.291015625
▁patients 0.0009145736694335938
, 3.38671875
▁ultimately 3.583984375
▁determ 2.53125
ining 1.9550323486328125e-05
▁their 0.493408203125
▁suit 0.5380859375
ability 1.3232231140136719e-05
▁for 0.10113525390625
▁bro 3.3984375
ader 8.177757263183594e-05
▁clin 0.8115234375
ical 0.00014913082122802734
▁use 0.4560546875
. 0.02679443359375
<0x0A> 0.05072021484375
S 6.46875
cient 1.5185546875
ists 1.2041015625
▁and 2.037109375
▁research 1.73046875
ers 0.0037479400634765625
▁world 1.6220703125
wide 0.0018129348754882812
▁are 1.01171875
▁eager 1.9580078125
ly 0.017578125
▁monitoring 5.15234375
▁Ch 1.3173828125
iros 0.0011653900146484375
cience 8.058547973632812e-05
' 0.07781982421875
s 0.00012993812561035156
▁ground 8.1171875
bre 0.103515625
aking 8.344650268554688e-07
▁efforts 1.888671875
, 0.26708984375
▁acknowled 5.4609375
ging 0.00038933753967285156
▁the 0.201171875
▁ur 4.20703125
gent 0.10198974609375
▁need 0.0238189697265625
▁for 0.0379638671875
▁novel 1.7099609375
▁th 2.537109375
era 1.7881393432617188e-06
pe 7.152557373046875e-07
ut 7.140636444091797e-05
ic 0.09588623046875
▁options 1.328125
▁in 0.763671875
▁the 0.13623046875
▁fight 0.89697265625
▁against 0.00018990039825439453
▁cancer 0.01049041748046875
. 0.006069183349609375
▁The 1.2021484375
▁potential 3.28125
▁success 3.974609375
▁of 0.0096588134765625
▁these 0.269775390625
▁human 2.689453125
▁tri 0.03521728515625
als 4.410743713378906e-06
▁could 0.51318359375
▁potentially 5.71875
▁p 1.6962890625
ave 0.00026106834411621094
▁the 0.0016870498657226562
▁way 0.005710601806640625
▁to 6.47265625
▁a 1.25
▁new 1.0458984375
▁era 0.192626953125
▁of 0.279296875
▁cancer 1.146484375
▁treatment 0.2410888671875
, 0.06011962890625
▁offering 1.4580078125
▁hope 0.33740234375
▁to 0.51318359375
▁count 2.416015625
less 1.1324882507324219e-05
▁individuals 0.8193359375
▁impact 3.94921875
ed 3.2901763916015625e-05
▁by 0.00015342235565185547
▁this 0.1502685546875
▁disease 3.65234375
. 0.09735107421875
<0x0A> 0.0718994140625
Con 2.7109375
clusion 0.0161590576171875
: 0.01349639892578125
<0x0A> 4.875
Ch 1.53125
iros 0.0025119781494140625
cience 5.054473876953125e-05
▁Group 0.04534912109375
▁pl 0.01366424560546875
c 2.5987625122070312e-05
' 0.25244140625
s 0.0001970529556274414
▁recent 2.212890625
▁announ 0.10064697265625
cement 0.0021343231201171875
▁regarding 3.51953125
▁the 0.0941162109375
▁init 0.0994873046875
iation 1.2993812561035156e-05
▁of 0.00015616416931152344
▁human 0.005901336669921875
▁tri 0.00307464599609375
als 7.152557373046875e-07
▁for 0.0203857421875
▁two 0.09814453125
▁prom 0.480712890625
ising 3.039836883544922e-05
▁anti 0.01042938232421875
- 8.082389831542969e-05
can 0.00030231475830078125
cer 2.5033950805664062e-05
▁comp 0.0013790130615234375
ounds 0.00045990943908691406
▁has 3.58203125
▁generated 1.353515625
▁optim 4.7578125
ism 0.0509033203125
▁and 1.236328125
▁excitement 0.5068359375
▁within 0.382568359375
▁the 0.006504058837890625
▁scientific 0.64208984375
▁community 0.033538818359375
. 0.10614013671875
▁As 2.443359375
▁profession 10.6171875
als 0.0011987686157226562
▁across 2.4609375
▁the 1.583984375
▁glo 0.43212890625
be 7.62939453125e-06
▁eager 2.236328125
ly 3.743171691894531e-05
▁await 0.305908203125
▁the 0.036285400390625
▁outcome 1.90234375
▁of 0.015167236328125
▁these 0.2242431640625
▁tri 0.1767578125
als 9.179115295410156e-06
, 0.0271759033203125
▁the 1.6298828125
▁potential 1.8681640625
▁for 0.75830078125
▁a 2.083984375
▁break 2.810546875
through 1.6450881958007812e-05
▁in 0.09381103515625
▁cancer 0.43310546875
▁research 3.66015625
▁hang 6.7890625
s 5.8770179748535156e-05
▁in 0.048004150390625
▁the 0.000762939453125
▁balance 0.01219940185546875
. 0.16552734375
▁Ch 2.66015625
iros 0.0009427070617675781
cience 6.341934204101562e-05
' 0.41259765625
s 0.0001277923583984375
▁rel 3.171875
ent 3.933906555175781e-06
less 8.058547973632812e-05
▁dedic 2.599609375
ation 4.410743713378906e-06
▁to 0.11834716796875
▁finding 1.71875
▁innov 0.234375
ative 0.00023412704467773438
▁solutions 0.045013427734375
▁offers 5.90625
▁a 0.64013671875
▁g 0.28466796875
limp 3.392578125
se 1.1920928955078125e-07
▁into 1.6923828125
▁the 0.5390625
▁future 0.358642578125
, 2.369140625
▁where 0.53564453125
▁cancer 1.04296875
▁treatment 1.3359375
▁may 0.94384765625
▁be 1.5029296875
▁po 5.71875
ised 3.123283386230469e-05
▁for 0.9365234375
▁a 0.2239990234375
▁transform 2.27734375
ative 0.2486572265625
▁le 3.162109375
ap 8.285045623779297e-05
, 6.28125
▁providing 3.47265625
▁renew 3.3203125
ed 3.135204315185547e-05
▁hope 0.0156402587890625
▁and 1.451171875
▁improved 3.935546875
▁out 0.6279296875
comes 0.0018434524536132812
▁for 0.024688720703125
▁cancer 1.703125
▁patients 0.00616455078125
▁world 0.46728515625
wide 6.437301635742188e-05
. 0.011138916015625
